Slayback Pharma LLC

Azurity Pharmaceuticals, Inc.

Girish Kumar Jain

Paras P Jain

Ajay Kumar Singh

Girish G Kore

Hanimi Reddy Bapatu

Keerthi Priya

Sandeep Jain

Praveen Kumar Subbappa

Sushant Omprakash Dube

Purushottam Sakhahari Pattewar

Venkateshwar Reddy Keesara

Purushottam Dattatraya Kulkarni

Josh Chandy Mathew

Balakrishna Reddy Akula

Kumarswamy Ummiti

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., C, AUCand/or AUC) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Pharmaceutical compositions of nilotinib

Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., T, C, AUCand/or AUC) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Pharmaceutical compositions of Lurasidone

Pharmaceutical compositions of lurasidone

The present invention relates to liquid pharmaceutical compositions of baclofen or a pharmaceutically acceptable salt thereof. More specifically, stable liquid pharmaceutical compositions of baclofen at concentrations of 5 mg/mL or more are provided. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and stable at pH ranges of 5-8 over a variety of storage conditions, including long-term storage for extended periods of time.

Liquid pharmaceutical compositions of baclofen for oral administration

Delayed-release pharmaceutical compositions prepared by hot-melt extrusion are provided, where the compositions comprise an azole anti-fungal drug having poor water solubility, an enteric polymer and a non-enteric polymer, and wherein the pharmaceutical composition may be orally administered to a patient in either the fed or fasted state. Preferably, the delayed-release pharmaceutical compositions prepared by hot-melt extrusion comprise posaconazole, HPMC-AS and HPC. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (T, C, AUCand/or AUC) of the azole anti-fungal drug, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Pharmaceutical compositions of posaconazole

Growing community of inventors

Maharashtra, India

Girish Kumar Jain